Heart Disease News and Research

Latest Heart Disease News and Research

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.

21 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

IDEV includes two stents to SUPERA product line for treating patients with peripheral vascular disease

IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients with peripheral vascular disease with the addition of two longer stents to its SUPERA product line.

21 Oct 2010

Cerenis raises €10 million in second close of Series C financing

Cerenis Therapeutics, a biopharmaceutical company specializing in the research and development of novel therapies based on HDL to treat cardiovascular and other metabolic diseases, announced today it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the Series C to €50 million and the total equity investment raised to date by the Company to €117 million.

21 Oct 2010

Venn Life Sciences acquires French CRO

Venn Life Sciences a multinational Clinical Research Organisation (CRO) announced today that it has acquired French CRO, DCI.

21 Oct 2010

Major companies phase out BPA from food and beverage packaging

Major brand name companies including Hain Celestial, H.J. Heinz, ConAgra, and General Mills are taking a leadership role in responding to consumer market shifts as awareness about health hazards of the endocrine disrupting chemical bisphenol A (BPA) in food can linings rises.

21 Oct 2010

Female sex hormones help women survive after trauma

Women who have been severely injured are 14 percent more likely to survive than similarly injured men, according to a new Johns Hopkins study, a difference researchers believe may be due to the negative impact of male sex hormones on a traumatized immune system.

21 Oct 2010

Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

A common infection in children, strep throat can lead to problems with a child's heart, joints or brain if left untreated. And when the brain is involved, motor and mental functioning may be compromised, leading to syndromes such as attention deficit disorder and obsessive-compulsive disorder (OCD).

21 Oct 2010

FDA asks manufacturers to add new warnings to labeling of prostate cancer drugs

The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer.

21 Oct 2010

Researcher identifies two risk markers for Alzheimer's disease

Risk markers could play an important role in this. These are substances linked to Alzheimer's that are found in unusually high or unusually low quantities in patients who go on to develop the disease.

21 Oct 2010

Hormone therapy associated with increased risk of death from breast cancer

Results of a new Women's Health Initiative (WHI) report show that hormone therapy is associated with an increased the risk of death from breast cancer, as well as an increased risk of developing invasive breast cancer in postmenopausal women.

21 Oct 2010

Stereotaxis launches Odyssey Interventional Network portal for global cardiovascular community

Stereotaxis, Inc. announced today that it launched the Odyssey Interventional Network, a training and educational video sharing web portal for the global cardiovascular community. The portal will showcase innovative electrophysiology (EP) and interventional cardiology (IC) procedures from leading centers around the world.

21 Oct 2010

Eating whole grains and limiting refined grains reduce body fat

People who consume several servings of whole grains per day while limiting daily intake of refined grains appear to have less of a type of fat tissue thought to play a key role in triggering cardiovascular disease and type 2 diabetes, a new study suggests. Researchers at the Jean Mayer USDA Human Nutrition Researcher Center on Aging (USDA HNRCA) at Tufts University observed lower volumes of visceral adipose tissue (VAT) in people who chose to eat mostly whole grains instead of refined grains.

21 Oct 2010

Plant-derived compound for treatment of nicotine addiction also effective against alcoholism

South Dakota State University researchers have demonstrated for the first time that a plant-derived compound used to treat nicotine addiction also has significant effects against alcohol addiction.

21 Oct 2010

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.

21 Oct 2010

Researchers suggest 'watch and wait' strategy for girls with germ-cell ovarian tumors

Researchers from Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) have found that as many as 50 percent of young girls treated for germ-cell ovarian tumors might safely be spared chemotherapy using a "watch and wait" strategy to determine if the follow-up treatment is needed.

21 Oct 2010

Hormone therapy increases breast cancer mortality risk, study finds

Hormone treatment after menopause, already known to increase the risk of breast cancer, also makes it more likely that the cancer will be advanced and deadly, a study finds.

21 Oct 2010

Aastrom submits SPA for Phase 3 clinical development program in critical limb ischemia to FDA

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a special protocol assessment (SPA) describing the company's proposed Phase 3 clinical development program in critical limb ischemia (CLI).

21 Oct 2010